Results 81 to 90 of about 3,103 (173)

Efficacy of Long-Acting Injectable Cabotegravir and Rilpivirine Compared With Daily Oral Antiretroviral Therapy in Patients With HIV: A Systematic Review. [PDF]

Cureus
Endara-Mina J, Quishpe M, Vera E, Haro N, Guzmán A, Guillin J, Quisnancela K, Sarmiento-Vallejo H, Mantilla-Alcivar I, Cabrera C, Cueva J, Serrano S, Caiza C, Intriago C, Salazar P.   +14 more
europepmc   +1 more source

Multidimensional Electron Diffraction-Microscopy of Cabotegravir Nanocrystals [PDF]

Microscopy and Microanalysis, 2019
Duncan N. Johnstone, Royston C. B. Copley, Rachel G. Graves, Jeffrey Brum, Paul A. Midgley   +4 more
openaire   +1 more source

Cabotegravir

Reactions Weekly
  +5 more sources

Neuropsychiatric Tolerability of Long-Acting Cabotegravir and Rilpivirine in People With HIV With Prior INSTI-Related CNS Toxicity: A Real-World Cohort Study. [PDF]

Open Forum Infect Dis
Rosas Cancio-Suárez M, Moreno A, Terrón SDC, Vivancos MJ, Vélez Díaz-Pallarés M, Casado JL, Cano C, Navarro-Soler R, Moreno S, Pérez-Elías MJ.   +9 more
europepmc   +1 more source

Recent Developments in HIV Antivirals: The Prospect of Prophylactic Drugs to Change the Pandemic. [PDF]

Microb Biotechnol
Brüssow H.
europepmc   +1 more source

Deltoid Administration of LAI-ART: Pharmacokinetic Implications When the Gluteal Site Is Not Feasible. [PDF]

Infez Med
Cossu MV, D'Avolio A, Ridolfo AL, Moschese D, Gori A, Cattaneo D, Gervasoni C.   +6 more
europepmc   +1 more source

The safety of cabotegravir in pregnancy: a systematic review and meta-analysis. [PDF]

BMC Infect Dis
Jasper A, Fourie W, Chetty S.
europepmc   +1 more source

Correction to: Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions. [PDF]

Open Forum Infect Dis
europepmc   +1 more source

[Early virological failure with long-acting cabotegravir/rilpivirine: description of two cases]. [PDF]

Rev Esp Quimioter
Pena-López MJ, Torres-Martel EG, Santana-Baez S, Bosch-Guerra X.   +3 more
europepmc   +1 more source

Authors’ response: Addressing the blind spot of self-reported adherence in the era of long-acting PrEP

Eurosurveillance
on behalf of the authors of the original article
doaj   +1 more source